Traders assign just 7.5% odds to a new COVID variant of concern before 2027 because current SARS-CoV-2 evolution remains anchored in JN.1-descendant lineages, with XFG (Stratus) as the dominant global strain and no recent WHO designations of variants of concern. Updated monovalent vaccines targeting XFG received FDA approval in late August 2026 for the 2026-2027 season, reflecting stable antigenic drift rather than abrupt shifts. More divergent lineages such as BA.3.2 show limited fitness and cocirculate at low levels without displacing prevailing variants or driving increased severity. High population immunity, reduced surveillance gaps, and the short remaining window through year-end further dampen the probability of a qualifying new variant of concern emerging in time to alter the outcome.